Home
ASND
ASND News

Latest Ascendis Pharma A/S (ASND) News on June 21, 2025

Exploring 3 High Growth Tech Stocks in the US Market

Simply Wall St.

21 hours ago

Exploring 3 High Growth Tech Stocks in the US Market

Exploring Three High Growth Tech Stocks In The US Market

Simply Wall St.

2 days ago

Exploring Three High Growth Tech Stocks In The US Market

Exploring High Growth Tech Opportunities in US Markets

Simply Wall St.

4 days ago

Exploring High Growth Tech Opportunities in US Markets

Ascendis Pharma (ASND) Rated as a Hold at Cannacord Genuity on Growth Hormone Prospects

Insider Monkey

4 days ago

Ascendis Pharma (ASND) Rated as a Hold at Cannacord Genuity on Growth Hormone Prospects

BofA Hikes Ascendis Pharma Price Target to $216 Affirms Buy Rating

Insider Monkey

5 days ago

BofA Hikes Ascendis Pharma Price Target to $216 Affirms Buy Rating

Ascendis Pharma price target raised to $224 from $215 at Oppenheimer

TipRanks

7 days ago

Ascendis Pharma price target raised to $224 from $215 at Oppenheimer

MT Newswires

8 days ago

Oppenheimer Raises Price Target on Ascendis Pharma to $224 From $215, Maintains Outperform Rating

TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26

Insider Monkey

9 days ago

TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26

MT Newswires

11 days ago

Ascendis Pharma Set to Exceed Q2 Expectations, RBC Says

Ascendis reports interim analysis outcomes from achondroplasia trial

Clinical Trials Arena

11 days ago

Ascendis reports interim analysis outcomes from achondroplasia trial

TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial

GlobeNewswire

12 days ago

TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial

MT Newswires

19 days ago

Ascendis' New Drug Application for Investigational Drug to Treat Genetic Disorder Accepted by FDA for Priority Review

FDA Accepts TransCon® CNP NDA for Priority Review

GlobeNewswire

19 days ago

FDA Accepts TransCon® CNP NDA for Priority Review

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.

a month ago

Exploring 3 High Growth Tech Stocks In The US Market

Ascendis Pharma A/S (ASND): Among the Best Growth Stocks to Buy and Hold for the Long Term

Insider Monkey

a month ago

Ascendis Pharma A/S (ASND): Among the Best Growth Stocks to Buy and Hold for the Long Term

New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)

GlobeNewswire

a month ago

New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)

New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism

GlobeNewswire

a month ago

New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism

Launch of New Drug Lifted Ascendis Pharma A/S (ASND) in Q1

Insider Monkey

a month ago

Launch of New Drug Lifted Ascendis Pharma A/S (ASND) in Q1

MT Newswires

2 months ago

Ascendis Likely to Benefit From Promising Yorvipath Launch, Morgan Stanley Says

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025

GlobeNewswire

2 months ago

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025

MT Newswires

2 months ago

Morgan Stanley Upgrades Ascendis Pharma to Overweight From Equalweight, Boosts Price Target to $250 From $180

Ascendis Pharma A/S (NASDAQ:ASND) Just Released Its First-Quarter Earnings: Here's What Analysts Think

Simply Wall St.

2 months ago

Ascendis Pharma A/S (NASDAQ:ASND) Just Released Its First-Quarter Earnings: Here's What Analysts Think

Ascendis Pharma First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

2 months ago

Ascendis Pharma First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

MT Newswires

2 months ago

RBC Raises Price Target on Ascendis Pharma to $210 From $205, Keeps Outperform, Speculative Risk

Ascendis Pharma AS (ASND) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ...

GuruFocus.com

2 months ago

Ascendis Pharma AS (ASND) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ...

MT Newswires

2 months ago

Ascendis Pharma Q1 Loss Narrows, Revenue Rises

Ascendis Pharma Reports First Quarter 2025 Financial Results

GlobeNewswire

2 months ago

Ascendis Pharma Reports First Quarter 2025 Financial Results

Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025

GlobeNewswire

2 months ago

Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025

Reddit initiated, Target downgraded: Wall Street’s top analyst calls

TipRanks

2 months ago

Reddit initiated, Target downgraded: Wall Street’s top analyst calls

Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?

Zacks

2 months ago

Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?

MT Newswires

2 months ago

RBC Initiates Ascendis Pharma at Outperform, Speculative Risk With $205 Price Target

Is Ascendis Pharma A/S (ASND) the Best Growth Stock to Buy According to Billionaires?

Insider Monkey

2 months ago

Is Ascendis Pharma A/S (ASND) the Best Growth Stock to Buy According to Billionaires?

High Growth Tech Stocks In US With Potential For Expansion

Simply Wall St.

2 months ago

High Growth Tech Stocks In US With Potential For Expansion

MT Newswires

3 months ago

Ascendis Pharma Files New Drug Application for Achondroplasia Medication

Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia

GlobeNewswire

3 months ago

Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia

Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock?

Zacks

3 months ago

Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock?

Exploring US High Growth Tech Stocks In March 2025

Simply Wall St.

4 months ago

Exploring US High Growth Tech Stocks In March 2025

Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference

GlobeNewswire

4 months ago

Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference

Ascendis Pharma A/S (NASDAQ:ASND) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Simply Wall St.

4 months ago

Ascendis Pharma A/S (NASDAQ:ASND) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Ascendis Pharma Full Year 2024 Earnings: Beats Expectations

Simply Wall St.

4 months ago

Ascendis Pharma Full Year 2024 Earnings: Beats Expectations

Ascendis Pharma AS (ASND) Q4 2024 Earnings Call Highlights: Strategic Growth and Market ...

GuruFocus.com

4 months ago

Ascendis Pharma AS (ASND) Q4 2024 Earnings Call Highlights: Strategic Growth and Market ...

Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?

Benzinga

4 months ago

Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?

MT Newswires

4 months ago

Ascendis Pharma Allocates $25 Million for Share Repurchases, Net Settlement of RSUs

MT Newswires

4 months ago

Ascendis Pharma Q4 Loss Narrows, Revenue Rises -- Shares Up After Hours

Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs

GlobeNewswire

4 months ago

Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs

Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire

4 months ago

Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results

Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025

GlobeNewswire

4 months ago

Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025

Alibaba Cloud integrates DeepSeek’s AI models

Verdict

5 months ago

Alibaba Cloud integrates DeepSeek’s AI models

Exploring High Growth Tech Stocks In January 2025

Simply Wall St.

5 months ago

Exploring High Growth Tech Stocks In January 2025

Is Ascendis Pharma (ASND) the High Growth International Stock to Invest in Now?

Insider Monkey

5 months ago

Is Ascendis Pharma (ASND) the High Growth International Stock to Invest in Now?

MT Newswires

5 months ago

BioMarin Pharmaceutical Sues Ascendis Pharma for Alleged Patent Infringement in Germany

Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

5 months ago

Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

5 months ago

Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains?

Zacks

6 months ago

Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains?

YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults

GlobeNewswire

6 months ago

YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults

Ascendis Pharma Finalizes Key Collaboration with Novo Nordisk

TipRanks

6 months ago

Ascendis Pharma Finalizes Key Collaboration with Novo Nordisk

New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26

GlobeNewswire

6 months ago

New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26

MT Newswires

6 months ago

Ascendis Pharma's Supplemental BLA for Adult Growth Hormone Deficiency Drug Accepted by FDA

FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

GlobeNewswire

6 months ago

FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

Exploring Three High Growth Tech Stocks in the United States

Simply Wall St.

6 months ago

Exploring Three High Growth Tech Stocks in the United States

Er-Kim and Ascendis’ endocrine therapy agreement extended in Eurasia

Pharmaceutical Technology

6 months ago

Er-Kim and Ascendis’ endocrine therapy agreement extended in Eurasia

MT Newswires

7 months ago

Ascendis Pharma Q3 Loss Narrows, Revenue Rises

Ascendis Pharma Reports Third Quarter 2024 Financial Results

GlobeNewswire

7 months ago

Ascendis Pharma Reports Third Quarter 2024 Financial Results

Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

GlobeNewswire

7 months ago

Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

High Growth Tech Stocks In The United States To Watch

Simply Wall St.

7 months ago

High Growth Tech Stocks In The United States To Watch

Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RA

Pharmaceutical Technology

8 months ago

Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RA

Novo Nordisk Secures License for Ascendis Pharma's Obesity Drug Technology

GuruFocus.com

8 months ago

Novo Nordisk Secures License for Ascendis Pharma's Obesity Drug Technology

Ascendis Pharma and Novo Nordisk Join Forces

TipRanks

8 months ago

Ascendis Pharma and Novo Nordisk Join Forces

Ascendis Pharma granted Novo exclusive worldwide license to TransCon platform

TipRanks

8 months ago

Ascendis Pharma granted Novo exclusive worldwide license to TransCon platform

Ozempic maker Novo Nordisk is working on a once-monthly weight-loss drug

Quartz

8 months ago

Ozempic maker Novo Nordisk is working on a once-monthly weight-loss drug

Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug

Benzinga

8 months ago

Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug

MT Newswires

8 months ago

Ascendis, Novo Nordisk to Develop, Commercialize Products in Metabolic, Cardiovascular Diseases

Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases

GlobeNewswire

8 months ago

Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases

Ascendis Pharma submits sBLA for growth hormone deficiency therapy

Pharmaceutical Technology

9 months ago

Ascendis Pharma submits sBLA for growth hormone deficiency therapy

High Growth Tech Stocks To Watch In October 2024

Simply Wall St.

9 months ago

High Growth Tech Stocks To Watch In October 2024

MT Newswires

9 months ago

Ascendis Pharma Submits Supplemental Biologics License Application for Pediatric Growth Hormone Drug

New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024

GlobeNewswire

9 months ago

New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024

Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

GlobeNewswire

9 months ago

Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish

Benzinga

9 months ago

BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish

MT Newswires

9 months ago

Sector Update: Health Care Stocks Rise Premarket Friday

MT Newswires

9 months ago

Ascendis Pharma Prices Offering of American Depositary Shares

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

GlobeNewswire

9 months ago

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

MT Newswires

9 months ago

Ascendis Pharma Unveils $300 Million ADS Offering

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

GlobeNewswire

9 months ago

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

Ascendis Soars on Encouraging Data From Dwarfism Drug Study

Zacks

9 months ago

Ascendis Soars on Encouraging Data From Dwarfism Drug Study

Ascendis Pharma (ASND) Moves 17.1% Higher: Will This Strength Last?

Zacks

9 months ago

Ascendis Pharma (ASND) Moves 17.1% Higher: Will This Strength Last?

GuruFocus.com

9 months ago

RA Capital Management's Strategic Acquisition of Fulcrum Therapeutics Shares

Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug

Investor's Business Daily

9 months ago

Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug

Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term

Benzinga

9 months ago

Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term

MT Newswires

9 months ago

Ascendis Pharma Says Trial of Potential Dwarfism Drug Achieved Primary Endpoint

Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

GlobeNewswire

9 months ago

Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

Ascendis Pharma A/S (ASND): Among Hedge Funds’ Top Biotech Stock Picks

Insider Monkey

9 months ago

Ascendis Pharma A/S (ASND): Among Hedge Funds’ Top Biotech Stock Picks

MT Newswires

9 months ago

Ascendis Says Initial Data Shows Anti-Tumor Activity in Phase 1/2 Platinum-Resistant Ovarian Cancer Trial

Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024

GlobeNewswire

9 months ago

Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024

MT Newswires

9 months ago

Ascendis Pharma Gets FDA Orphan Drug Designation for Hypoparathyroidism Treatment

Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults

GlobeNewswire

9 months ago

Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults

Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In

Benzinga

10 months ago

Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In

Why Ascendis Pharma Stock Tumbled by 11% Today

Motley Fool

10 months ago

Why Ascendis Pharma Stock Tumbled by 11% Today

Ascendis Pharma Undercuts 50-Day Line After Pricing Fiasco Prompts Guidance Cut

Investor's Business Daily

10 months ago

Ascendis Pharma Undercuts 50-Day Line After Pricing Fiasco Prompts Guidance Cut

MT Newswires

10 months ago

Sector Update: Health Care Stocks Fall Premarket Wednesday

Share on Social Networks: